Anebulo Pharmaceuticals
Developing innovative, life-saving therapies that will improve the lives of millions of patients struggling with substance use disorders.
Launch date
Employees
Market cap
$53.9m
Enterprise valuation
$49m (Public information from Sep 2024)
Share price
$2 ANEB
Lakeway Texas (HQ)
Financials
Estimates*
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | 8.4m |
| EBITDA | (3.6m) | (6.8m) | (11.8m) | - | - | - |
| Profit | (30.3m) | (6.8m) | (11.7m) | (11.8m) | (17.9m) | (24.4m) |
| % profit margin | - | - | - | - | - | (290 %) |
| EV / revenue | - | - | - | - | - | 8.9x |
| EV / EBITDA | -38.5x | -15.7x | -4.2x | - | - | - |
| R&D budget | 2.3m | 3.0m | 5.6m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $21.0m | IPO | |
* | $6.6m | Private Placement VC | |
* | $1.9m | Grant | |
| Total Funding | $8.5m | ||